Clinical Trial

Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer

Study acronym: RAPSON
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 27, 2024 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC) Open-label, randomized phase II trial in patients with symptomatic bone-only metastatic castration-resistant prostate cancer. Eligible patients are randomly assigned into two arms: * Arm A: radium-223 initially followed by docetaxel plus prednisone at the time of progression (the second step is optional according to clinical evolution of disease) * Arm B: docetaxel plus prednisone initially followed by radium-223 at the time of progression (the second step is optional according to clinical evolution of disease).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2017-07-25; most recent amendment 2024-09-24.
Status change: Recruiting → Active, Not Recruiting 2024-09-24
Status change: Not Yet Recruiting → Recruiting 2017-12-18
Trial Details
NCT Number NCT03230734
Lead Sponsor Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Collaborators: Bayer
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 70 participants
Start Date 2017-09-01
Primary Completion 2025-07 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2024-09-27